DPP4 and bone fracture: A meta analysis performed by Monami et al. on all trials that enrolled T2DM patients that received DPP-4 inhibitors for at least 24 weeks suggested that DPP-4 inhibitors could be associated with reduced risk of bone fracture [52], but the duration of included trials was short and bone fracture were not the principal end points in any of the studies and were reported only as adverse events, and were probably not described carefully.